Search Results - "Castro, Javier De"

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial by Provencio, Mariano, Nadal, Ernest, Insa, Amelia, García-Campelo, María Rosario, Casal-Rubio, Joaquín, Dómine, Manuel, Majem, Margarita, Rodríguez-Abreu, Delvys, Martínez-Martí, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Pereira, Eva, Royuela, Ana, Casarrubios, Marta, Salas Antón, Clara, Parra, Edwin R, Wistuba, Ignacio, Calvo, Virginia, Laza-Briviesca, Raquel, Romero, Atocha, Massuti, Bartomeu, Cruz-Bermúdez, Alberto

“…Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of…”
Get full text

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis by Antonia, Scott J, Borghaei, Hossein, Ramalingam, Suresh S, Horn, Leora, De Castro Carpeño, Javier, Pluzanski, Adam, Burgio, Marco A, Garassino, Marina, Chow, Laura Q M, Gettinger, Scott, Crinò, Lucio, Planchard, David, Butts, Charles, Drilon, Alexander, Wojcik-Tomaszewska, Joanna, Otterson, Gregory A, Agrawal, Shruti, Li, Ang, Penrod, John R, Brahmer, Julie

“…Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab…”
Get full text

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis by Cejas, Paloma, López-Gómez, Miriam, Aguayo, Cristina, Madero, Rosario, de Castro Carpeño, Javier, Belda-Iniesta, Cristóbal, Barriuso, Jorge, Moreno García, Víctor, Larrauri, Javier, López, Rocío, Casado, Enrique, Gonzalez-Barón, Manuel, Feliu, Jaime

“…KRAS mutations in colorectal cancer primary tumors predict resistance to anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody therapy in patients…”
Get full text

Myeloid cells in vascular dementia and Alzheimer's disease: Possible therapeutic targets? by García‐Culebras, Alicia, Cuartero, María Isabel, Peña‐Martínez, Carolina, Moraga, Ana, Vázquez‐Reyes, Sandra, Castro‐Millán, Francisco Javier, Cortes‐Canteli, Marta, Lizasoain, Ignacio, Moro, María Ángeles

“…Growing evidence supports the suggestion that the peripheral immune system plays a role in different pathologies associated with cognitive impairment, such as…”
Get full text

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry by Conde, Esther, Suárez-Gauthier, Ana, Benito, Amparo, Garrido, Pilar, García-Campelo, Rosario, Biscuola, Michele, Paz-Ares, Luis, Hardisson, David, de Castro, Javier, Camacho, M Carmen, Rodriguez-Abreu, Delvys, Abdulkader, Ihab, Ramirez, Josep, Reguart, Noemí, Salido, Marta, Pijuán, Lara, Arriola, Edurne, Sanz, Julián, Folgueras, Victoria, Villanueva, Noemí, Gómez-Román, Javier, Hidalgo, Manuel, López-Ríos, Fernando

“…Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been…”
Get full text

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer by Blackhall, Fiona, Ross Camidge, D, Shaw, Alice T, Soria, Jean-Charles, Solomon, Benjamin J, Mok, Tony, Hirsh, Vera, Jänne, Pasi A, Shi, Yuankai, Yang, Pan-Chyr, Pas, Tommaso De, Hida, Toyoaki, Carpeño, Javier De Castro, Lanzalone, Silvana, Polli, Anna, Iyer, Shrividya, Reisman, Arlene, Wilner, Keith D, Kim, Dong-Wan

“…PurposeCrizotinib is a potent, orally administered tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced…”
Get full text

DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through MAFG Overexpression in Cancer Cells by Vera, Olga, Jimenez, Julia, Pernia, Olga, Rodriguez-Antolin, Carlos, Rodriguez, Carmen, Sanchez Cabo, Fatima, Soto, Javier, Rosas, Rocio, Lopez-Magallon, Sara, Esteban Rodriguez, Isabel, Dopazo, Ana, Rojo, Federico, Belda, Cristobal, Alvarez, Rafael, Valentin, Jaime, Benitez, Javier, Perona, Rosario, De Castro, Javier, Ibanez de Caceres, Inmaculada

“…One of the major limitations associated with platinum use is the resistance that almost invariably develops in different tumor types. In the current study, we…”
Get full text

Sperm selection by thermotaxis improves ICSI outcome in mice by Pérez-Cerezales, Serafín, Laguna-Barraza, Ricardo, de Castro, Alejandro Chacón, Sánchez-Calabuig, María Jesús, Cano-Oliva, Esther, de Castro-Pita, Francisco Javier, Montoro-Buils, Luis, Pericuesta, Eva, Fernández-González, Raúl, Gutiérrez-Adán, Alfonso

“…The ejaculate is a heterogeneous pool of spermatozoa containing only a small physiologically adequate subpopulation for fertilization. As there is no method to…”
Get full text

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy by Casarrubios, Marta, Provencio, Mariano, Nadal, Ernest, Insa, Amelia, del Rosario García-Campelo, María, Lázaro-Quintela, Martín, Dómine, Manuel, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez-Marti, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Massuti, Bartomeu, Sierra-Rodero, Belén, Martinez-Toledo, Cristina, Fernández-Miranda, Ismael, Serna-Blanco, Roberto, Romero, Atocha, Calvo, Virginia, Cruz-Bermúdez, Alberto

“…BackgroundNeoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with…”
Get full text

The impact of next-generation sequencing on the DNA methylation–based translational cancer research by Soto, Javier, Rodriguez-Antolin, Carlos, Vallespín, Elena, de Castro Carpeño, Javier, Ibanez de Caceres, Inmaculada

“…Epigenetics is currently in an exponential phase of growth, constituting one of the most promising fields in science, particularly in cancer research. Impaired…”
Get full text

482 COVID-19 in patients with lung cancer receiving immunotherapy. A report from an spanish academic center by Viñal, David, Gutierrez, Laura, Villamayor, Julia, Higuera, Oliver, Cabrero, Dario Sanchez, Castro, Javier De

“…BackgroundCOVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared pandemic in March 2020. We know that patients with…”
Get full text

Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms by Saini, Kamal S, de Las Heras, Begoña, Plummer, Ruth, Moreno, Victor, Romano, Marco, de Castro, Javier, Aftimos, Philippe, Fredriksson, Judy, Bhattacharyya, Gouri Shankar, Olivo, Martin Sebastian, Schiavon, Gaia, Punie, Kevin, Garcia-Foncillas, Jesus, Rogata, Ernesto, Pfeiffer, Richie, Orbegoso, Cecilia, Morrison, Kenneth, Curigliano, Giuseppe, Chin, Lynda, Saini, Monika Lamba, Rekdal, Øystein, Anderson, Steven, Cortes, Javier, Leone, Manuela, Dancey, Janet, Twelves, Chris, Awada, Ahmad

Get full text

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib by Vishwanathan, Karthick, Dickinson, Paul A., So, Karen, Thomas, Karen, Chen, Yuh‐Min, De Castro Carpeño, Javier, Dingemans, Anne‐Marie C., Kim, Hye Ryun, Kim, Joo‐Hang, Krebs, Matthew G., Chih‐Hsin Yang, James, Bui, Khanh, Weilert, Doris, Harvey, R. Donald

“…Aims We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor…”
Get full text

Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME) by Schnabel, Philipp A, Smit, Egbert, Carpeño, Javier de Castro, Leśniewski-Kmak, Krzysztof, Aerts, Joachim, Kraaij, Kees, Visseren-Grul, Carla, Dyachkova, Yulia, Taipale, Kaisa, Girvan, Allicia, Moro-Sibilot, Denis

“…Abstract FRAME is a prospective observational study of first-line treatments for advanced non-small cell lung cancer (NSCLC). This interim analysis examines…”
Get full text

ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications by SERENO, Maria, CEJAS, Paloma, MORENO, Víctor, BELDA-INIESTA, Cristóbal, LOPEZ, Rocio, NISTAL, Manuel, FELIU, Jaime, CASTRO CARPENO, Javier De

“…Small cell lung cancer is the most aggressive lung cancer subtype. The standard treatment approach is based on cisplatin regimens. Although response rates to…”
Get full text

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas by Lin, Chia-Chi, Arkenau, Hendrik-Tobias, Lu, Sharon, Sachdev, Jasgit, de Castro Carpeño, Javier, Mita, Monica, Dziadziuszko, Rafal, Su, Wu-Chou, Bobilev, Dmitri, Hughes, Lorraine, Chan, Jian, Zhang, Zhi-Yi, Weiss, Glen J.

“…Background Anaplastic lymphoma kinase ( ALK ) gene rearrangements are oncogenic drivers in non-small-cell lung cancer (NSCLC). TSR-011 is a dual ALK and…”
Get full text

miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients by Sanchez-Cabrero, Darío, Garcia-Guede, Álvaro, Burdiel, Miranda, Pernía, Olga, Colmenarejo-Fernandez, Julián, Gutierrez, Laura, Higuera, Oliver, Rodriguez, Isabel Esteban, Rosas-Alonso, Rocío, Rodriguez-Antolín, Carlos, Losantos-García, Itsaso, Vera, Olga, De Castro-Carpeño, Javier, Ibanez de Caceres, Inmaculada

“…Despite advances in non-small cell lung cancer (NSCLC) research, this is still the most common cancer type that has been diagnosed up to date. microRNAs have…”
Get full text

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer by Borghaei, Hossein, Gettinger, Scott, Vokes, Everett E, Chow, Laura Q M, Burgio, Marco Angelo, de Castro Carpeno, Javier, Pluzanski, Adam, Arrieta, Oscar, Frontera, Osvaldo Arén, Chiari, Rita, Butts, Charles, Wójcik-Tomaszewska, Joanna, Coudert, Bruno, Garassino, Marina Chiara, Ready, Neal, Felip, Enriqueta, García, Miriam Alonso, Waterhouse, David, Domine, Manuel, Barlesi, Fabrice, Antonia, Scott, Wohlleber, Markus, Gerber, David E, Czyzewicz, Grzegorz, Spigel, David R, Crino, Lucio, Eberhardt, Wilfried Enst Erich, Li, Ang, Marimuthu, Sathiya, Brahmer, Julie

“…Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057),…”
Get full text

Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer by Gutierrez-Sainz, Laura, Cruz-Castellanos, Patricia, Higuera, Oliver, de Castro-Carpeño, Javier

“…Opinion statement Worldwide, lung cancer is the most common cause of cancer morbidity and mortality. Despite a trend towards an escalating diagnosis of…”
Get full text

Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy by Guijarro-Eguinoa, Javier, Arjona-Hernandez, Sara, Stewart, Stefan, Pernia, Olga, Arias, Pedro, Losantos-García, Itsaso, Rubio, Tania, Burdiel, Miranda, Rodriguez-Antolin, Carlos, Cruz-Castellanos, Patricia, Higuera, Oliver, Borobia, Alberto M, Rodriguez-Novoa, Sonia, de Castro-Carpeño, Javier, Ibanez de Caceres, Inmaculada, Rosas-Alonso, Rocio

“…Platin-based chemotherapy is the standard treatment for patients with non-small cell lung cancer (NSCLC). However, resistance to this therapy is a major…”
Get full text